Abdel-Razeq Rashid, Bitar Lynn, Bitar Elio R, Onwuzo Chidera, Abu-Hammour Mohamad-Noor, Eren Barish, Mohamed Islam, Johnson Adejoke, Boustany Antoine, Onwuzo Somtochukwu, Asaad Imad
Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44111, United States.
Faculty of Medicine, Saint Joseph University of Beirut, Beirut 1104 2020, Lebanon.
World J Hepatol. 2024 Oct 27;16(10):1169-1176. doi: 10.4254/wjh.v16.i10.1169.
() is associated with the development of gastrointestinal disorders ranging from gastritis to gastric cancer. The evidence of the association between metabolic dysfunction-associated steatohepatitis (MASH) and infection in the literature is scarce. Therefore, we aim to evaluate the risk of developing MASH in patients who have had a diagnosis of infection independently of any confounding variables.
To evaluate the risk of developing MASH in patients who have had a diagnosis of infection.
This study used a validated multicenter research database of over 360 hospitals across 26 healthcare systems across the United States from 1999 to 2022. Multivariate regression analysis assessed the risk of developing MASH, adjusting for confounders including infection, obesity, type 2 diabetes, hypertension, dyslipidemia, and male gender. A two-sided value < 0.05 was considered as statistically significant, and all statistical analyses were performed using R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria, 2008).
A total of 79476132 individuals were screened in the database and 69232620 were selected in the final analysis after accounting for inclusion and exclusion criteria. Smokers (14.30%), patients with hyperlipidemia (70.35%), hypertension (73.86%), diabetes mellitus type 2 (56.46%), and obese patients (58.15%) were more common in patients with MASH compared to control. Using a multivariate regression analysis, the risk of MASH was increased in diabetics [odds ratio (OR): 3.55; 95%CI: 3.48-3.62], obese (OR: 5.93; 95%CI: 5.81-6.04), males (OR: 1.49; 95%CI: 1.46-1.52), individuals with hyperlipidemia (OR: 2.43; 95%CI: 2.38-2.49) and infection (OR: 2.51; 95%CI: 2.31-2.73).
This is the largest population-based study in the United States illustrating an increased prevalence and odds of developing MASH in patients with infection after adjusting for risk factors.
（）与从胃炎到胃癌等一系列胃肠道疾病的发生有关。代谢功能障碍相关脂肪性肝炎（MASH）与感染之间关联的文献证据稀少。因此，我们旨在评估独立于任何混杂变量的情况下，已确诊感染的患者发生MASH的风险。
评估已确诊感染的患者发生MASH的风险。
本研究使用了一个经过验证的多中心研究数据库，该数据库涵盖了1999年至2022年美国26个医疗系统中360多家医院的数据。多变量回归分析评估了发生MASH的风险，并对包括感染、肥胖、2型糖尿病、高血压、血脂异常和男性性别等混杂因素进行了调整。双侧P值<0.05被认为具有统计学意义，所有统计分析均使用R 4.0.2版本（R统计计算基金会，奥地利维也纳，2008年）进行。
数据库中共筛查了79476132人，根据纳入和排除标准，最终分析纳入69232620人。与对照组相比，吸烟者（14.30%）、高脂血症患者（70.35%）、高血压患者（73.86%）、2型糖尿病患者（56.46%）和肥胖患者（58.15%）在MASH患者中更为常见。使用多变量回归分析，糖尿病患者发生MASH的风险增加[比值比（OR）：3.55；95%置信区间（CI）：3.48 - 3.62]，肥胖患者（OR：5.93；95%CI：5.81 - 6.04），男性（OR：1.49；95%CI：1.46 - 1.52），高脂血症患者（OR：2.43；95%CI：2.38 - 2.49）和感染患者（OR：2.51；95%CI：2.31 - 2.73）。
这是美国最大的一项基于人群的研究，表明在调整风险因素后，感染患者发生MASH的患病率和几率增加。
